ストックスクリーナーアプリを入手
5.81
1.93%
0.11
アフターアワーズ：
5.83
0.02
+0.34%
前日終値:
$5.70
開ける：
$5.67
24時間の取引高:
770.03K
Relative Volume:
0.60
時価総額：
$395.56M
収益：
$380.79M
当期純損益:
$49.27M
株価収益率:
-4.6855
EPS:
-1.24
ネットキャッシュフロー:
$10.68M
1週間 パフォーマンス:
+14.60%
1か月 パフォーマンス:
+86.22%
6か月 パフォーマンス:
+186.21%
1年 パフォーマンス:
-68.48%
1日の値動き範囲:
$5.53
$5.83
1週間の範囲:
$5.06
$5.83
52週間の値動き範囲:
$1.575
$19.95
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
名前
Amylyx Pharmaceuticals Inc
セクター
電話
617-683-0917
住所
43 THORNDIKE STREET, CAMBRIDGE
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-01-03 | 開始されました | Robert W. Baird | Outperform |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-07-24 | アップグレード | Goldman | Neutral → Buy |
| 2023-03-31 | 開始されました | Mizuho | Buy |
| 2023-01-05 | 開始されました | BofA Securities | Buy |
| 2022-05-25 | 開始されました | Citigroup | Buy |
| 2022-04-01 | ダウングレード | Goldman | Buy → Neutral |
すべてを表示
Amylyx Pharmaceuticals Inc (AMLX) 最新ニュース
Amylyx Pharmaceuticals (AMLX) to Release Earnings on Thursday - MarketBeat
Vanguard Group Inc's Strategic Reduction in Amylyx Pharmaceutica - GuruFocus.com
There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise - Simply Wall St
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 - StockTitan
abrdn plc Buys 1,853,995 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Levi & Korsinsky Reminds Amylyx Investors of the Pending Class A - GuruFocus.com
Short Interest in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Declines By 21.1% - MarketBeat
Perceptive Advisors LLC's Strategic Acquisition in Amylyx Pharmaceuticals Inc - Yahoo Finance
Amylyx upgraded to buy by BofA on hypoglycemia drug potential - MSN
BofA upgrades Amylyx stock to Buy rating By Investing.com - Investing.com Australia
BofA upgrades Amylyx stock to Buy rating - Investing.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded to Buy by Bank of America - MarketBeat
Levi & Korsinsky Announces the Filing of a Securities Class Acti - GuruFocus.com
Amylyx Pharmaceuticals reports results from pancreatic disease treatment trial - MSN
Amylyx Pharmaceuticals (AMLX): Leading Nano Cap in Neurodegenerative Disease Treatments - Insider Monkey
Why Amylyx Pharmaceuticals Stock Was So Healthy This Week - MSN
Amylyx shares reiterate Buy rating on trial data - Investing.com
Amylyx shares reiterate Buy rating on trial data By Investing.com - Investing.com UK
Amylyx Pharmaceuticals (NASDAQ:AMLX) Receives "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright maintains Buy rating on Amylyx shares on trial data - Investing.com
H.C. Wainwright maintains Buy rating on Amylyx shares on trial data By Investing.com - Investing.com UK
Amylyx’s AMX0035 shows promise in Phase II Wolfram syndrome trial - Clinical Trials Arena
PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug - Yahoo Finance
Leerink maintains Market Perform rating on Amylyx stock on new data - Investing.com
Leerink maintains Market Perform rating on Amylyx stock on new data By Investing.com - Investing.com South Africa
Amylyx reports positive trial results for Wolfram syndrome treatment - Investing.com India
Amylyx reports positive trial results for Wolfram syndrome treatment By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome - Business Wire
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024 - BioSpace
Amyotrophic Lateral Sclerosis Market 2034 | Mitsubishi Tanabe - openPR
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by Millennium Management LLC - MarketBeat
Deutsche Bank Initiates Coverage of Amylyx Pharmaceuticals (AMLX) with Buy Recommendation - MSN
Brokerages Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Target Price at $17.60 - MarketBeat
American Century Companies Inc. Reduces Stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
AQR Capital Management LLC Acquires 3,224,454 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm - Marketscreener.com
Amylyx Pharmaceuticals executive sells over $27k in company stock - Investing.com India
Amylyx Pharmaceuticals executive sells over $27k in company stock By Investing.com - Investing.com Canada
Amylyx Pharmaceuticals executive sells over $36k in company stock - Investing.com
Amylyx Pharmaceuticals executive sells over $36k in company stock By Investing.com - Investing.com Australia
Insider Selling: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Sells 11,442 Shares of Stock - MarketBeat
Amylyx Pharmaceuticals CEO sells over $59k in stock By Investing.com - Investing.com South Africa
Amylyx Co-CEO sells over $59,000 in company stock By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals CEO sells over $59k in stock - Investing.com
Amylyx Co-CEO sells over $59,000 in company stock - Investing.com
Amylyx Pharmaceuticals Navigates Shift to Smaller Reporting Status: Impacts on Investor Relations and Stock Volatility - TipRanks
Amyotrophic Lateral Sclerosis Treatment Market is Booming with - openPR
Almitas Capital LLC Makes New Investment in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals Inc (AMLX) 財務データ
収益
当期純利益
現金流量
EPS
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):